Tourmaline Bio, Inc. (TRML)
NASDAQ: TRML · Real-Time Price · USD
16.87
-0.45 (-2.60%)
Apr 25, 2025, 4:00 PM EDT - Market closed
Tourmaline Bio Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Tourmaline Bio stock have an average target of 49.33, with a low estimate of 25 and a high estimate of 70. The average target predicts an increase of 192.41% from the current stock price of 16.87.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Tourmaline Bio stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 4 | 4 | 4 | 4 | 3 |
| Buy | 0 | 2 | 2 | 3 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 6 | 6 | 7 | 8 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Chardan Capital | Chardan Capital | Strong Buy Initiates $70 | Strong Buy | Initiates | $70 | +314.94% | Apr 23, 2025 |
| Wedbush | Wedbush | Buy Maintains $42 → $43 | Buy | Maintains | $42 → $43 | +154.89% | Mar 14, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $49 → $50 | Strong Buy | Maintains | $49 → $50 | +196.38% | Mar 14, 2025 |
| Wedbush | Wedbush | Buy Initiates $42 | Buy | Initiates | $42 | +148.96% | Mar 6, 2025 |
| LifeSci Capital | LifeSci Capital | Buy Initiates $58 | Buy | Initiates | $58 | +243.81% | Feb 24, 2025 |
Financial Forecast
Revenue This Year
112.87M
from 23.14M
Increased by 387.73%
Revenue Next Year
n/a
from 112.87M
EPS This Year
-3.55
from -2.89
EPS Next Year
-4.23
from -3.55
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 63.0M | 63.0M | 63.0M | ||
| Avg | 7.7M | 7.7M | 14.1M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 172.2% | 723.5% | 723.5% | ||
| Avg | -66.9% | - | 84.7% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.89 | -2.98 | -2.99 | ||
| Avg | -3.55 | -4.23 | -5.16 | ||
| Low | -4.56 | -5.85 | -9.44 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.